LaserBond Dec 24 Appendix 4D & Financial Report
Stock | Laserbond Ltd (LBL.ASX) |
---|---|
Release Time | 21 Feb 2025, 8:23 a.m. |
Price Sensitive | Yes |
LaserBond Reports Stable 1H25 Revenue, Outlines Growth Initiatives
- Revenue in line with AGM guidance, Services Division up 16.8%
- Significant investment in leadership, capabilities and capacity to drive future growth
- US expansion plans progressing, focused on high-demand markets and global customer support
In 1H25, LaserBond achieved stable revenue, in line with AGM guidance, as the company continued executing its strategic plan for accelerated growth. This required significant investment, which impacted profitability in the half but has been critical in establishing a platform for future growth. The Services Division delivered impressive 16.8% revenue growth, while the Products Division experienced volatility from one of its major OEM customers. To support the company's growth objectives, LaserBond invested $1.41 million, or 84.8% of statutory before-tax profits, in expanding its senior leadership team, driving industry and customer spending through targeted business development, increasing capabilities via capital investment, and reducing lead times through recruitment, training and improved capacity utilization. These initiatives are expected to begin delivering benefits in 2H25. LaserBond's US expansion plans also progressed, with research and analysis confirming the multiple advantages and optimal locations for a local facility to capture markets where the company's proprietary technology is highly sought. The company continues to be highly confident in its future, targeting 2H25 revenue growth of 9.4% to 23.6% and profit before tax growth of 80% to 134% compared to 1H25.
2H25 revenue forecast of $22.2 to $25.1 million, representing growth of 9.4% to 23.6% on 1H25. Profit before tax estimated to be between $2.4 and $3.1 million, representing 80% to 134% growth on 1H25.
LaserBond continues to be highly confident in its future, with the significant investments made in 1H25 expected to begin delivering benefits in 2H25 and beyond. The company is well-positioned to capture growth opportunities in its target markets, both domestically and through its planned US expansion.